166 related articles for article (PubMed ID: 19673697)
1. Recent patents reveal microtubules as persistent promising target for novel drug development for cancers.
Bughani U; Li S; Joshi HC
Recent Pat Antiinfect Drug Discov; 2009 Nov; 4(3):164-82. PubMed ID: 19673697
[TBL] [Abstract][Full Text] [Related]
2. Taking aim at a dynamic target: Noscapinoids as microtubule-targeted cancer therapeutics.
Lopus M; Naik PK
Pharmacol Rep; 2015 Feb; 67(1):56-62. PubMed ID: 25560576
[TBL] [Abstract][Full Text] [Related]
3. Rational design of novel microtubule targeting anticancer drugs N-imidazopyridine noscapinoids: Chemical synthesis and experimental evaluation based on in vitro using breast cancer cells and in vivo using xenograft mice model.
Pragyandipta P; Pedapati RK; Reddy PK; Nayek A; Meher RK; Guru SK; Kantevari S; Naik PK
Chem Biol Interact; 2023 Sep; 382():110606. PubMed ID: 37330181
[TBL] [Abstract][Full Text] [Related]
4. Rational design of the microtubule-targeting anti-breast cancer drug EM015.
Aneja R; Lopus M; Zhou J; Vangapandu SN; Ghaleb A; Yao J; Nettles JH; Zhou B; Gupta M; Panda D; Chandra R; Joshi HC
Cancer Res; 2006 Apr; 66(7):3782-91. PubMed ID: 16585205
[TBL] [Abstract][Full Text] [Related]
5. Insights into the structure and tubulin-targeted anticancer potential of N-(3-bromobenzyl) noscapine.
Cheriyamundath S; Mahaddalkar T; Reddy Nagireddy PK; Sridhar B; Kantevari S; Lopus M
Pharmacol Rep; 2019 Feb; 71(1):48-53. PubMed ID: 30465924
[TBL] [Abstract][Full Text] [Related]
6. Rational design of biaryl pharmacophore inserted noscapine derivatives as potent tubulin binding anticancer agents.
Santoshi S; Manchukonda NK; Suri C; Sharma M; Sridhar B; Joseph S; Lopus M; Kantevari S; Baitharu I; Naik PK
J Comput Aided Mol Des; 2015 Mar; 29(3):249-70. PubMed ID: 25481458
[TBL] [Abstract][Full Text] [Related]
7. A new antiproliferative noscapine analogue: chemical synthesis and biological evaluation.
Ghaly PE; Abou El-Magd RM; Churchill CD; Tuszynski JA; West FG
Oncotarget; 2016 Jun; 7(26):40518-40530. PubMed ID: 27777381
[TBL] [Abstract][Full Text] [Related]
8. Identification of novel and improved antimitotic agents derived from noscapine.
Anderson JT; Ting AE; Boozer S; Brunden KR; Crumrine C; Danzig J; Dent T; Faga L; Harrington JJ; Hodnick WF; Murphy SM; Pawlowski G; Perry R; Raber A; Rundlett SE; Stricker-Krongrad A; Wang J; Bennani YL
J Med Chem; 2005 Nov; 48(23):7096-8. PubMed ID: 16279766
[TBL] [Abstract][Full Text] [Related]
9. Tubulin inhibitors as novel anticancer agents: an overview on patents (2013-2018).
Haider K; Rahaman S; Yar MS; Kamal A
Expert Opin Ther Pat; 2019 Aug; 29(8):623-641. PubMed ID: 31353978
[No Abstract] [Full Text] [Related]
10. In silico inspired design and synthesis of a novel tubulin-binding anti-cancer drug: folate conjugated noscapine (Targetin).
Naik PK; Lopus M; Aneja R; Vangapandu SN; Joshi HC
J Comput Aided Mol Des; 2012 Feb; 26(2):233-47. PubMed ID: 22170255
[TBL] [Abstract][Full Text] [Related]
11. Novel third-generation water-soluble noscapine analogs as superior microtubule-interfering agents with enhanced antiproliferative activity.
Henary M; Narayana L; Ahad S; Gundala SR; Mukkavilli R; Sharma V; Owens EA; Yadav Y; Nagaraju M; Hamelberg D; Tandon V; Panda D; Aneja R
Biochem Pharmacol; 2014 Nov; 92(2):192-205. PubMed ID: 25124704
[TBL] [Abstract][Full Text] [Related]
12. Rational design of novel anti-microtubule agent (9-azido-noscapine) from quantitative structure activity relationship (QSAR) evaluation of noscapinoids.
Santoshi S; Naik PK; Joshi HC
J Biomol Screen; 2011 Oct; 16(9):1047-58. PubMed ID: 21972248
[TBL] [Abstract][Full Text] [Related]
13. Targeting microtubules for cancer chemotherapy.
Zhou J; Giannakakou P
Curr Med Chem Anticancer Agents; 2005 Jan; 5(1):65-71. PubMed ID: 15720262
[TBL] [Abstract][Full Text] [Related]
14. Noscapine and its Analogs as Chemotherapeutic Agent: Current updates.
Tomar V; Kukreti S; Prakash S; Madan J; Chandra R
Curr Top Med Chem; 2017; 17(2):174-188. PubMed ID: 27237331
[TBL] [Abstract][Full Text] [Related]
15. Nanosolvated microtubule-modulating chemotherapeutics: a case-to-case study.
Jain V; Jain B; Tiwari P; Saini J; Jain UK; Pandey RS; Kumar M; Katare OP; Chandra R; Madan J
Anticancer Drugs; 2013 Apr; 24(4):327-36. PubMed ID: 23411683
[TBL] [Abstract][Full Text] [Related]
16. Microtubule Targeting Agents as Cancer Chemotherapeutics: An Overview of Molecular Hybrids as Stabilizing and Destabilizing Agents.
Tangutur AD; Kumar D; Krishna KV; Kantevari S
Curr Top Med Chem; 2017; 17(22):2523-2537. PubMed ID: 28056738
[TBL] [Abstract][Full Text] [Related]
17. Induction of acetylation and bundling of cellular microtubules by 9-(4-vinylphenyl) noscapine elicits S-phase arrest in MDA-MB-231 cells.
Cheriyamundath S; Mahaddalkar T; Kantevari S; Lopus M
Biomed Pharmacother; 2017 Feb; 86():74-80. PubMed ID: 27939522
[TBL] [Abstract][Full Text] [Related]
18. Rational design of 9-vinyl-phenyl noscapine as potent tubulin binding anticancer agent and evaluation of the effects of its combination on Docetaxel.
Dash SG; Suri C; Nagireddy PKR; Kantevari S; Naik PK
J Biomol Struct Dyn; 2021 Sep; 39(14):5276-5289. PubMed ID: 32608323
[TBL] [Abstract][Full Text] [Related]
19. Tubulin inhibitors: a patent review.
Liu YM; Chen HL; Lee HY; Liou JP
Expert Opin Ther Pat; 2014 Jan; 24(1):69-88. PubMed ID: 24313741
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of di-substituted noscapine analogs as potent and microtubule-targeted anticancer agents.
Mishra RC; Gundala SR; Karna P; Lopus M; Gupta KK; Nagaraju M; Hamelberg D; Tandon V; Panda D; Reid MD; Aneja R
Bioorg Med Chem Lett; 2015; 25(10):2133-40. PubMed ID: 25891106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
